Autologous Gamma Delta T Cells therapy(H Lee Moffitt Cancer Center & Research Institute)

N/A

Report date: 2024/01/16 20:00:39

Base Information

Drug NameAutologous Gamma Delta T Cells therapy(H Lee Moffitt Cancer Center & Research Institute)
Drug Alias NameAutologous Gamma Delta T Cells Genetically Engineered With a Chimeric Receptor Cells therapy(H Lee Moffitt Cancer Center & Research Institute)Autologous Gamma Delta T Cells Genetically Engineered with a Chimeric Receptor to Target the Prostate Stem Cell Antigen therapy(H Lee Moffitt Cancer Center & Research Institute)MSGV1-PSCA-8T28Z
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsProstatic Neoplasms, Castration-Resistant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesH Lee Moffitt Cancer Center & Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesH Lee Moffitt Cancer Center & Research Institute
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-Resistant
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A